Icon (NASDAQ:ICLR) Director John Dr Climax Sells 5,005 Shares of Stock

Icon Plc (NASDAQ:ICLR) Director John Climax sold 5,005 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $875,875.00. Following the sale, the director owned 2,087 shares of the company’s stock, valued at $365,225. This represents a 70.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

John Dr Climax also recently made the following trade(s):

• On Tuesday, August 11th, John Climax sold 841 shares of Icon stock. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89.

Icon Price Performance

Icon stock opened at $164.11 on Friday. The company’s 50 day simple moving average is $167.19 and its 200-day simple moving average is $140.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company has a market capitalization of $12.57 billion, a price-to-earnings ratio of 38.52, a price-to-earnings-growth ratio of 7.85 and a beta of 1.20.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business posted $3.26 EPS. As a group, equities research analysts expect that Icon Plc will post 9.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. TD Cowen raised their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research report on Thursday, June 25th. Barclays boosted their price target on shares of Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 25th. Mizuho increased their price objective on Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Friday, June 26th. Finally, William Blair upgraded Icon to a “strong-buy” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $170.07.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ICLR. Abound Financial LLC acquired a new stake in shares of Icon in the 4th quarter valued at $54,000. GAMMA Investing LLC lifted its position in shares of Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after purchasing an additional 69 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Icon by 207.5% during the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares in the last quarter. Global Retirement Partners LLC grew its stake in shares of Icon by 308.2% during the fourth quarter. Global Retirement Partners LLC now owns 547 shares of the medical research company’s stock worth $100,000 after purchasing an additional 413 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in Icon by 1,062.0% in the first quarter. Fifth Third Bancorp now owns 918 shares of the medical research company’s stock valued at $102,000 after buying an additional 839 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About Icon

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.